GeneDx is a publicly-traded clinical genomics company (NASDAQ: WGS) specializing in exome and genome sequencing for rare and ultra-rare genetic disorders, primarily in pediatric and neonatal populations. Founded in 2000 in Gaithersburg, Maryland by NIH scientists Sherri Bale and John Compton, GeneDx was acquired by BioReference Laboratories in 2006 for approximately $17 million, later coming under OPKO Health when OPKO acquired BioReference. In April 2022, Sema4 Holdings (a SPAC-merged AI-driven genomic and clinical data platform that had gone public via combination with CM Life Sciences in July 2021) acquired GeneDx from OPKO/BioReference for roughly $623 million. Sema4 subsequently renamed itself GeneDx Holdings Corp. in January 2023 and began trading under the ticker WGS. The combined company has refocused on rare disease diagnostics, exiting reproductive health testing and consolidating around the GeneDx genomic testing platform. GeneDx maintains its clinical laboratory and a major operational footprint in Gaithersburg, MD while corporate headquarters sit in Stamford, Connecticut.
GeneDx is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2000
Employees
1,200–1,400
Total Funding
$241M
2 rounds
Latest Valuation
$1B
July 29, 2020
Total raised $241M across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series C
Date
July 29, 2020
Amount
$121M
Valuation
$1B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| July 29, 2020 | Series C | $121M | $1B | BlackRock |
| August 30, 2019 | Series B | $120M | — | Blackstone |
Katherine Stueland
President & Chief Executive Officer
Kevin Feeley
Chief Financial Officer
Matthew Davis
Chief Technology & Product Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Natera
Publicly traded (NASDAQ: NTRA) genetic testing company specializing in cell-free DNA testing across oncology, women's health, and organ health; competes in clinical genomics and inherited disease testing.
Ambry Genetics
Clinical genomic diagnostics laboratory offering hereditary cancer testing and exome sequencing for rare diseases. Acquired by Tempus in November 2024.
Invitae
Medical genetics company providing genetic testing across hereditary cancer, rare disease, and reproductive health; emerged from Chapter 11 in 2024 with assets acquired by Labcorp.
23andMe
Direct-to-consumer and clinical genetic testing company; less rare-disease focused but competes in broader genomic diagnostics market.
PreventionGenetics
Clinical genetic testing laboratory specializing in DNA sequencing for inherited diseases; subsidiary of Exact Sciences.
MedGenome
Genomics-driven research and diagnostics company providing clinical genetic testing services with operations across North America and Asia.
GeneDx is publicly listed on NASDAQ under ticker WGS. The company became public through a series of transactions: predecessor entity Sema4 went public via a SPAC merger with CM Life Sciences (NASDAQ: CMLF) on July 23, 2021, trading as SMFR. Sema4 then acquired GeneDx from OPKO/BioReference Laboratories in April 2022 for ~$623M, and in January 2023 renamed itself GeneDx Holdings Corp., with shares trading under the new ticker WGS starting January 10, 2023. A 1-for-33 reverse stock split took effect May 4, 2023.
GeneDx shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
GeneDx had a valuation of approximately $1B at the time of its public offering. Current market capitalization fluctuates with the share price.
GeneDx raised $241M across 2 disclosed funding rounds prior to its public listing.
GeneDx is headquartered in Stamford, CT.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.